Skip to main content

Advertisement

Table 2 Disease specific characteristics of patients with Rheumatoid Arthritis

From: Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study

RA phenotype Data expressed as Patients with RA, n = 68
Disease duration, years median (IQR) 17.3 (10.7, 25.7) (range 5.4, 43.4)
Early morning stiffness, mins median (IQR) 13 (0, 45) (n = 62)
History of orthopaedic joint surgery n (%) 19 (29.7)
Number of orthopaedic joint surgical episodes n (%) 9 (14.1) - 1 episode
3 (4.7) - 2 episodes
5 (7.8) - 3 episodes
2 (3.1) - 4 episodes
Current use of oral prednisolone n (%) 3 (4.7)
Current use of csDMARD n (%) 52 (81.3)
Number of csDMARDs currently taking n (%) 40 (62.5) taking 1
8 (12.5) taking 2
6 (9.4) taking 3
Number of previously tried csDMARDs median (IQR) 2 (1, 3) (range 0, 7)
Current use of biological DMARD n (%) 43 (67.2)
 Current TNFI users 19 (29.7)
 Current rituximab users 21 (32.8)
 Current tocilizumab users 2 (3.1)
 Current abatacept user 1 (1.6)
Number of treatment cycles in current RTX users median (IQR) 4 (3, 5.5) (range 2, 9)
Number of previously tried biological DMARDs median (IQR) 0 (0, 1)
Patient general health VAS median (IQR) 31 (16, 53) (n = 59)
TJC28 median (IQR) 2 (0, 6)
SJC28 median (IQR) 0 (0, 1)
HAQ-DI median (IQR) 1.50 (0.53, 2.00) (n = 60)
3-variable DAS28-CRP median (IQR) 2.38 (1.15, 3.25)
Erosions on hands/feet x-ray n (%) 50/61 (82)
CRP (mg/L) median (IQR) 0 (0, 8.3)
ESR (mm/h) median (IQR) 14 (6, 28) (n = 59)
RF positive (≥ 40 iu/ml) n (%) 44 (68.8)
ACPA positive (≥ 10 U/ml) n (%) 50/63 (79.4)
  1. ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, csDMARDs conventional synthetic DMARDs, DAS28-CRP 28-joint disease activity score based on CRP, DMARDs disease-modifying anti-rheumatic drugs, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, RF rheumatoid factor, RTX rituximab, SJC swollen joint count, TJC tender joint count, VAS visual assessment score